AI x Bio Summit: Co-Founder Transon Nguyen describes how AI is enabling Eigen Therapeutics to become a discovery engine for priming therapies

blonca9
Jul 25, 2024
1 min read

He explains how the goal of Eigen is to help up-regulate antigens of interest and how technologies today allow a smaller startup to derive and test large datasets.

Recent Posts

See All

Talking chromatin regulation at Foghorn Therapeutics - whose partner Lilly will have preclinical data at AACR highlighting how the lead SMARCA2 program could do in combinations with other therapies

AI news: Epicrispr Biotechnologies' CEO Amber Salzman describes how her company will be utilizing AI muscle analysis in its clinical study for facioscapulohumeral muscular dystrophy

Lexeo Therapeutics' CEO Nolan Townsend highlights recent FA cardiomyopathy data and the path ahead in that indication. Plus, the latest on PKP2 ACM, and more

AI x Bio Summit: Co-Founder Transon Nguyen describes how AI is enabling Eigen Therapeutics to become a discovery engine for priming therapies

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight